Recursion & Exscientia shareholders approve combination; close expected Nov 20

RECURSION PHARMACEUTICALS, INC.

Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
Transaction expected to close on November 20, 2024, subject to remaining customary conditions.
Chris Gibson, Ph.D., to remain CEO of the combined company post-closing.
Update call on Nov 20 at 7:30 a.m. ET; details on X, LinkedIn, YouTube.
Final voting results to be filed via 8-K and 6-K with SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.